BDX Becton Dickinson Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
23:45
Aug 06
Aug 06
Cheap medtech with AI-driven growth
BD (Becton Dickinson) is cheap at 14x forward earnings after a strong quarter. The post-split portfolio is number one in 90% of markets, with secular growth in connected care, AI, robotics, and GLP-1 delivery devices, making it a durable consistency play.
HIGH
12:00
Aug 06
Aug 06
Management raised full-year revenue and EPS guidance based on strong Q3 performance and broad-based momentum, signaling confidence in continued execution.
HIGH
10:32
Aug 06
Aug 06
Becton Dickinson beats Q3 2026 earnings estimates with adjusted EPS of 3.23 dollars and revenue.
Becton Dickinson beats Q3 2026 earnings estimates with adjusted EPS of 3.23 dollars and revenue of 5 billion dollars.
12:00
Aug 04
Aug 04
China's flow research business, which declined 30% in the first quarter, improved to a mid-single-digit decline in Q2 after doubling export license approvals, a 25-percentage-point swing. — The rapid improvement in export license processing is a direct operational fix that could unlock demand in a key market, positively impacting the acquired flow business.
HIGH
00:04
Jun 04
Jun 04
BDX at historically low valuation.
Becton Dickinson is at its lowest valuation relative to the market in history, making it a bargain. Buy now.
HIGH
23:44
May 07
May 07
BD strong quarter, AI healthcare growth.
Becton Dickinson reported a strong quarter with a top and bottom line beat, raised full-year earnings guidance, and has a portfolio that is 90% recurring revenue. The company is benefiting from AI in healthcare (patient monitoring), GLP-1 injectables, tissue regeneration, and home care solutions, making it a compelling investment.
HIGH
12:00
May 07
May 07
Management raised full-year EPS guidance while reaffirming revenue, citing broad-based growth across 90% of the portfolio and strong BD Excellence-driven productivity, offsetting known headwinds.
HIGH
22:45
Apr 11
Apr 11
BDX is a scarce asset with margin of safety.
Becton Dickinson (BDX) is a world leader in syringes and catheters with over 50% market share, giving it scale economies, embeddedness in hospital systems, and a regenerative feedback loop for innovation. It trades at 12-13 times earnings (8% earnings yield), implying the market expects little growth, yet the company is focused, generates strong free cash flow, and uses it for dividends and buybacks. It is well-positioned to benefit from the growth of biologics and integration of technology like AI.
HIGH
13:30
Feb 12
Feb 12
Baxter is treating the lower IV solutions demand environment following Hurricane Helene as a 'new baseline', with fluid conservation practices entrenched in hospital workflows. — The company is not expecting a recovery in IV fluids volumes to pre-hurricane levels, which could signal lower structural demand for its own products and, potentially, its competitors in the space.
MED
13:30
Feb 09
Feb 09
Waters' chemistry pricing power is running ahead of plan, with ~400-450 bps of like-for-like price increases in chemistry and ~200 bps overall, which it plans to apply to the newly acquired BD business that historically only achieved ~40-50 bps. — Significant untapped pricing power exists in the acquired BD business, which could drive substantial margin and revenue upside if Waters successfully applies its playbook.
HIGH
13:00
Feb 09
Feb 09
BD delivered better-than-expected Q1 results, but management maintained a cautious full-year outlook. While growth areas like GLP-1s and Alaris share gains are strong, headwinds from vaccines, China VBP, and Alaris replacement cycle continue, offsetting a bullish tone on the long-term portfolio.
HIGH
23:29
Jan 23
Jan 23
Oral Wegovy threatens syringe makers.
Becton Dickinson and West Pharmaceutical Services fell on fears that Novo Nordisk's oral Wegovy will cannibalize the traditional injectable GLP-1 market, reducing demand for syringes and related medical supplies.
MED
22:50
Jan 23
Jan 23
Oral GLP-1 pills threaten syringe makers.
Positive commentary on Novo Nordisk's oral Wegovy pill is raising fears that patients will shift from injectable GLP-1s to pills, reducing demand for syringes and hitting syringe makers such as Becton Dickinson and West Pharmaceutical Services.
MED
21:30
Dec 04
Dec 04
Ulta's new CFO comes from a large healthcare conglomerate, signaling a focus on financial discipline but with no direct operational impact for BDX.
HIGH
About BDX Investor Commentary
Across the available history and selected sources, Buzzberg tracks BDX (Becton Dickinson) across 5 sources: 4 bullish vs 0 bearish calls from 12 authors. Historical directional balance: 29% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 14 total trade ideas tracked. Latest voices: Jim Cramer, Tom Polen, LiveSquawk.